Patents Assigned to Eisai R&D Management Co., Ltd.
  • Patent number: 11998544
    Abstract: This disclosure relates to methods for the treatment of neoplastic disorders by administering Compound 1, or a pharmaceutically acceptably salt thereof, on its own and/or as part of a conjugate or composition, and inducing production of at least one neoantigen.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: June 4, 2024
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Ermira Pazolli, Silvia Buonamici, James Palacino, Michael Seiler, Ping Zhu, Evan Barry, Lihua Yu
  • Patent number: 11945807
    Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: April 2, 2024
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Ermira Pazolli, Silvia Buonamici, Thiwanka Samarakoon, Sudeep Prajapati, Nathan Fishkin, James Palacino, Michael Seiler, Ping Zhu, Andrew Cook, Peter Smith, Xiang Liu, Shelby Ellery, Dominic Reynolds, Lihua Yu, Zhenhua Wu, Shouyong Peng, Nicholas Calandra, Megan Sheehan, Yonghong Xiao
  • Patent number: 11926619
    Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: March 12, 2024
    Assignee: Eisai R & D Management Co., Ltd.
    Inventors: Gregg F. Keaney, John Wang, Baudouin Gerard, Kenzo Arai, Xiang Liu, Guo Zhu Zheng, Kazunobu Kira, Lisa A. Marcaurelle, Marta Nevalainen, Ming-Hong Hao, Morgan Welzel O'Shea, Parcharee Tivitmahaisoon, Sudeep Prajapati, Tuoping Luo, Nicholas C. Gearhart, Jason T. Lowe, Yoshihiko Kotake, Satoshi Nagao, Regina Mikie Kanada Sonobe, Masayuki Miyano, Norio Murai, Andrew Cook, Shelby Ellery, Atsushi Endo, James Palacino, Dominic Reynolds
  • Patent number: 11925639
    Abstract: Provided is a pharmaceutical composition for treating a tumor, which is used in combination therapy of lenvatinib and (6S,9aS)—N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: March 12, 2024
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yoichi Ozawa, Yusaku Hori, Kazuhiko Yamada, Hiroshi Kamiyama, Masahiro Matsuki
  • Publication number: 20240060068
    Abstract: Gapmers or pharmaceutically acceptable salt of the gapmers and methods of making the gapmers are provided. The gapmers include a gap region that contains deoxyribonucleosides linked to each other by phosphorothioate bonds, a 5? wing region positioned at the 5? end of the gap region that contains morpholino monomers linked to each other by phosphorodiamidate bonds, and a 3? wing region positioned at the 3? end of the gap region that contains morpholino monomers linked to each other by phosphorodiamidate bonds. Antisense oligonucleotides are also provided. These antisense oligonucleotides are useful in the preparation of gapmers for inhibition of Tau mRNA transcription.
    Type: Application
    Filed: December 10, 2021
    Publication date: February 22, 2024
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Francis G. Fang, Dae-Shik Kim, Hyeong Wook Choi, Yoshinori Takahashi, Kenji Kikuta, Hikaru Kawashima, Wataru Itano, Toshiki Kurokawa, Tamaki Hoshikawa, Mingde SHAN, John Wang
  • Publication number: 20230406863
    Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, and medical uses thereof.
    Type: Application
    Filed: June 21, 2023
    Publication date: December 21, 2023
    Applicants: President and Fellows of Harvard College, Eisai R&D Management Co., LTD.
    Inventors: Yoshito Kishi, Kazunobu Kira, Ken Ito
  • Patent number: 11833119
    Abstract: Provided herein is a combination therapy useful for the treatment hepatocellular carcinoma. The combination comprises an FGFR4 inhibitor and lenvatinib.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: December 5, 2023
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Anand Selvaraj, Peter Smith
  • Patent number: 11833146
    Abstract: There is provided a therapeutic agent for Alzheimer's disease and Lewy body dementia for combined use of (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinoline-4(5H)-one represented by formula (1): or a pharmaceutically acceptable salt thereof, and donepezil represented by formula (II): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: December 5, 2023
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Mai Miyamoto, Sadaharu Kotani
  • Patent number: 11814398
    Abstract: The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.
    Type: Grant
    Filed: June 23, 2022
    Date of Patent: November 14, 2023
    Assignees: President and Fellows of Harvard College, Eisai R&D Management Co., LTD.
    Inventors: Yoshito Kishi, Kazunobu Kira, Ken Ito
  • Publication number: 20230301990
    Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.
    Type: Application
    Filed: March 7, 2023
    Publication date: September 28, 2023
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Andrew COOK, Dominic REYNOLDS, Cheng ZHONG, Ryan BRAWN, Shelby ELLERY, Thiwanka SAMARAKOON, Xiang LIU, Sudeep PRAJAPATI, Megan SHEEHAN, Jason T. LOWE, James PALACINO
  • Patent number: 11761045
    Abstract: Splice variants associated with neomorphic SF3B1 mutations are described herein. This application also relates to methods of detecting the described splice variants, and uses for diagnosing cancer, evaluating modulators of SF3B1, and methods of treating cancer associated with mutations in SF3B1.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: September 19, 2023
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Lihua Yu, Kian Huat Lim, Jacob D. Feala, Silvia Buonamici, Yoshiharu Mizui, Peter G. Smith, Ping Zhu, Eunice Sun Park, Michael W. Seiler, Marco Peter Fekkes
  • Patent number: 11753669
    Abstract: Provided herein are conjugated immunoglobulins and methods for generating conjugated immunoglobulins using a microbial transglutaminase.
    Type: Grant
    Filed: January 27, 2021
    Date of Patent: September 12, 2023
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Jared Spidel, Earl Albone
  • Publication number: 20230279018
    Abstract: The invention provides agents that inhibit L-Phe in cytoplasmic phenylalanine tRNA-synthetase (cFRS), methods for identifying them, compositions comprising such agents, and therapeutic methods of using such agents.
    Type: Application
    Filed: March 22, 2023
    Publication date: September 7, 2023
    Applicants: The Broad Institute, Inc., President and Fellows of Harvard College, Eisai R&D Management Co., LTD.
    Inventors: Eamon COMER, Bruno MELILLO, Francis G. FANG, Branko MITASEV
  • Patent number: 11725015
    Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, and medical uses thereof.
    Type: Grant
    Filed: February 4, 2021
    Date of Patent: August 15, 2023
    Assignees: President and Fellows of Harvard College, Eisai R&D Management Co., LTD.
    Inventors: Yoshito Kishi, Kazunobu Kira, Ken Ito
  • Publication number: 20230250182
    Abstract: Provided herein are methods of treating cancer (e.g., RCC) or von-Hippel Lindau disease, which comprise administering to a human patient in need thereof: (a) a PD-1 antagonist; (b) a HIF-2? inhibitor; and (c) lenvatinib, or a pharmaceutically acceptable salt thereof. Also provided are kits containing such agents and uses of therapeutic combinations of such agents for the treatment of cancer.
    Type: Application
    Filed: June 21, 2021
    Publication date: August 10, 2023
    Applicants: Merck Sharp & Dohme LLC, Eisai R&D Management Co., Ltd.
    Inventors: Rodolfo Fleury Perini, Elaine M. Pinheiro, Jacqueline Willemann-Rogerio
  • Patent number: 11707448
    Abstract: The present invention provides methods and compositions for treating cancer by administering an EP4 antagonist in combination with radiation therapy, antibody therapy and/or anti-metabolite chemotherapy.
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: July 25, 2023
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Xingfeng Bao, Diana Albu, Mary Woodall-Jappe
  • Publication number: 20230212679
    Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.
    Type: Application
    Filed: March 11, 2022
    Publication date: July 6, 2023
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Taro Semba, Yusuke Narita, Yukinori Minoshima, Atsumi Yamaguchi, Yusuke Adachi, Kazuhiko Yamada, Junji Matsui, Tadashi Kadowaki, Kentaro Takahashi, Yasuhiro Funahashi
  • Publication number: 20230210838
    Abstract: Provided herein are methods of treating cancer (e.g., RCC) or von-Hippel Lindau disease, which comprise administering to a human patient in need thereof: (a) a HIF-2? inhibitor; and (b) lenvatinib, or a pharmaceutically acceptable salt thereof. Also provided are kits containing such agents and uses of therapeutic combinations of such agents for the treatment of cancer or von-Hippel Lindau disease.
    Type: Application
    Filed: June 21, 2021
    Publication date: July 6, 2023
    Applicants: Merck Sharp & Dohme LLC, Eisai R&D Management Co., Ltd.
    Inventors: Rodolfo Fleury Perini, Elaine M. Pinheiro, Jacqueline Willemann-Rogerio
  • Patent number: 11691990
    Abstract: The present invention provides crystals of (1R,3R,15E,28R,29R,30R,31R,34R,36R,39S,41R)-29,41-Difluoro-34,39-bis(sulfanyl)-2,33,35,38,40,42-hexaoxa-4,6,9,11,13,18,20,22,25,27-decaaza-34?5,39?5-diphosphaoctacyclo[28.6.4.13,36.128,31.04,8.07,12.019,24.023,27]dotetraconta-5,7,9,11,15,19,21,23,25-nonaene-34,39-dione (Compound (I)) ammonium salts, Compound (I) sodium salts, or Compound (I), possessing a potential to be used as drug substance in pharmaceuticals.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: July 4, 2023
    Assignee: Eisai R&D Management Co., LTD
    Inventors: Jun Niijima, Hirofumi Kuroda, So Yasui, Yoko Ito, Ikuo Kushida
  • Patent number: D1032850
    Type: Grant
    Filed: January 20, 2023
    Date of Patent: June 25, 2024
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Rajeev Narayanan, David Levin, Alexander Scott